An e cient T-cell epitope discovery strategy using in silico prediction and the iTopia assay platform 
Fridman et al. Figure S1 . A strategy for in silico selection of T cell epitopes and analogs. Candidate epitopes were selected from tumor-associated antigens CEA, HER2, and TERT based on predicted binding to MHC-I alleles HLA-A1,A2, A3, A24, and B7; uniqueness in the human genome; and increased likelihood of natural processing. 123 native peptides and 102 fixed-anchor analogs of 98 of the native fragments were selected for testing in the iTopia assay, for a total of 225 peptides. Table S1 . CEA-and HER2-derived T cell epitopes found in other human proteins. 17 CEA-and 10 HER2-derived T cell epitopes previously suggested as candidates for tumor immunotherapy were found in other human proteins, including proteins not known to be tumor-associated. 
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